Company / R&D per Share
Ligand Pharmaceuticals, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.25
FY2025
5-year range
$1.22 / $4.25
FY2021-FY2025
Trend
+248.2%
vs FY2024
Sector context
#46 of 208
Health Care
What the data says
R&D per Share changed +248% YoY in FY2025, a notable deviation from the 9-year average annual change of +34%.
Based on SEC 10-K filings.
4.25 in FY2025 with a 5-year CAGR of +12.0%. Top quartile in the Health Care sector.
Improved from $1.45 to $4.25 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +25.5%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 208This company $4.25 Sector average $28.82
▼
-85.3% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 248.2% year-over-year.
- Ranks #46 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.25 | +248.2% |
| FY2024 | $1.22 | -15.7% |
| FY2023 | $1.45 | -32.7% |
| FY2022 | $2.15 | +7.8% |
| FY2021 | $2.00 | -17.1% |
| FY2020 | $2.41 | -10.6% |
| FY2019 | $2.69 | +104.4% |
| FY2018 | $1.32 | +2.5% |
| FY2017 | $1.29 | +20.9% |
| FY2016 | $1.06 | +89.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026